Tuesday’s Midday Movers: Bluebird Bio (BLUE), Clovis Oncology (CLVS), Sangamo Biosciences (SGMO), GW Pharma (GWPH)

By Carrie Williams

So far Tuesday, December 10, NASDAQ is up 0.45% and the S&P is up 0.14%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Bluebird Bio (BLUEResearch Report), Clovis Oncology (CLVSResearch Report), Sangamo Biosciences (SGMOResearch Report) and GW Pharma (GWPHResearch Report).

Bluebird Bio is up 8.6% in midday trading to $82.50. Shares opened today at $75.97. The company has a 52-week low of $71.42 and a 52-week high of $163.43. On the Street’s front, the average 12-month analyst price target for the stock is $116.63, marking a 53.52% potential upside from current levels. In a report released today, William Blair analyst Raju Prasad maintained a Hold rating on BLUE. Separately, yesterday, Maxim Group’s Jason McCarthy maintained a Buy rating on the stock and has a price target of $130.00.

Clovis Oncology is up 7.64% in midday trading to $11.84. Shares opened today at $11.00. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a 3.82% potential upside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which implies a downside of 27% from current levels. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00. In the last 30 days, insiders purchased $34.55K worth of CLVS shares.

Sangamo Biosciences is down -6.86% in midday trading to $9.44. Shares opened today at $10.13. The company has a 52-week low of $6.26 and a 52-week high of $13.91. On the Street’s front, the average 12-month analyst price target for the stock is $13.50, marking a 33.27% potential upside from current levels. In a report released today, Cowen analyst Ritu Baral assigned a Buy rating on SGMO. Separately, on November 12, Wedbush’s Liana Moussatos reiterated a Hold rating on the stock and has a price target of $11.00.

See today’s analyst top recommended stocks >>

GW Pharma is up 6.56% in midday trading to $102.84. Shares opened today at $96.50. The company has a 52-week low of $90.14 and a 52-week high of $196.00. On the Street’s front, the average 12-month analyst price target for the stock is $201.83, marking a 109.15% potential upside from current levels. In a report released yesterday, Cowen analyst Phil Nadeau maintained a Buy rating on GWPH, with a price target of $200.00, which represents a potential upside of 107% from where the stock is currently trading. In the last 30 days, insiders have sold $3.92M worth of GWPH shares. Over the last 3 months, the insider sentiment on GW Pharma has been negative based on 35 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>